Rosuvastatin to prevent vascular events in men and women with elevated C-reactive pro- tein. N Engl J Med. 2008;359:2195 207. S3.2.1-6. Randomised trial of cholesterol lowering in 4444 patients with coro- nary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383 9. S3.2.1-7. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cho- lesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615 22. S3.2.1-8. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investiga- tors. N Engl J Med. 1996;335:1001 9. S3.2.1-9. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301 7. S3.2.1-10. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349 57. S3.2.1-11. MRC/BHF Heart Protection Study of antioxidant vitamin supple- mentation in 20536 high-risk individuals: a randomised placebo- controlled trial. Lancet. 2002;360:23 33. S3.2.1-12. Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549 59. S3.2.1-13. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus mod- erate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495 504. S3.2.1-14. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425 35. S3.2.1-15. Nakamura H, Arakawa K, Itakura H, et al. 